loading
Schlusskurs vom Vortag:
$10.54
Offen:
$10.56
24-Stunden-Volumen:
42,426
Relative Volume:
0.17
Marktkapitalisierung:
$472.08M
Einnahmen:
$84.82M
Nettoeinkommen (Verlust:
$-21.43M
KGV:
-11.42
EPS:
-0.89
Netto-Cashflow:
$-27.23M
1W Leistung:
-12.29%
1M Leistung:
-30.18%
6M Leistung:
-19.06%
1J Leistung:
+93.26%
1-Tages-Spanne:
Value
$9.847
$10.91
1-Wochen-Bereich:
Value
$9.847
$11.65
52-Wochen-Spanne:
Value
$5.29
$20.90

Y Mabs Therapeutics Inc Stock (YMAB) Company Profile

Name
Firmenname
Y Mabs Therapeutics Inc
Name
Telefon
212-847-9841
Name
Adresse
230 PARK AVENUE, NEW YORK, NY
Name
Mitarbeiter
100
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-08
Name
Neueste SEC-Einreichungen
Name
YMAB's Discussions on Twitter

Vergleichen Sie YMAB mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
YMAB 10.18 472.08M 84.82M -21.43M -27.23M -0.89
VRTX 447.58 115.74B 10.63B -479.80M -1.35B 13.33
REGN 741.92 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 589.39 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.84 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 103.41 24.49B 3.30B -501.07M 1.03B 11.54

Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-08-16 Eingeleitet Cantor Fitzgerald Overweight
2024-06-28 Eingeleitet Truist Buy
2023-05-10 Hochstufung Wedbush Neutral → Outperform
2023-04-03 Herabstufung Guggenheim Buy → Neutral
2023-01-27 Herabstufung Morgan Stanley Equal-Weight → Underweight
2023-01-05 Herabstufung Cowen Outperform → Market Perform
2022-12-02 Herabstufung BofA Securities Buy → Neutral
2022-10-31 Herabstufung JP Morgan Neutral → Underweight
2022-10-31 Herabstufung Wedbush Outperform → Neutral
2022-07-06 Fortgesetzt Canaccord Genuity Buy
2022-06-24 Eingeleitet BMO Capital Markets Outperform
2022-02-03 Fortgesetzt Guggenheim Buy
2021-11-19 Fortgesetzt Morgan Stanley Equal-Weight
2021-11-16 Herabstufung JP Morgan Overweight → Neutral
2021-05-07 Hochstufung BofA Securities Neutral → Buy
2021-04-23 Fortgesetzt Cowen Outperform
2021-03-22 Fortgesetzt JP Morgan Overweight
2021-01-15 Herabstufung BofA Securities Buy → Neutral
2020-11-09 Bestätigt H.C. Wainwright Buy
2020-05-05 Eingeleitet Barclays Overweight
2020-05-01 Eingeleitet Janney Buy
2020-04-29 Eingeleitet Morgan Stanley Equal-Weight
2019-12-24 Eingeleitet JP Morgan Overweight
2019-11-20 Eingeleitet Guggenheim Buy
2019-09-04 Eingeleitet Wedbush Outperform
2019-04-01 Eingeleitet H.C. Wainwright Buy
2018-10-16 Eingeleitet BTIG Research Buy
2018-10-16 Eingeleitet BofA/Merrill Buy
Alle ansehen

Y Mabs Therapeutics Inc Aktie (YMAB) Neueste Nachrichten

pulisher
03:13 AM

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

03:13 AM
pulisher
Nov 20, 2024

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q3 2024 Earnings Call Transcript - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

Oppenheimer Begins Coverage on Y-mAbs Therapeutics (NASDAQ:YMAB) - Defense World

Nov 20, 2024
pulisher
Nov 20, 2024

Y-mAbs started at outperform at Oppenheimer on pre-targeted radiotherapies - MSN

Nov 20, 2024
pulisher
Nov 19, 2024

The Market Doesn't Like What It Sees From Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Revenues Yet As Shares Tumble 26% - Simply Wall St

Nov 19, 2024
pulisher
Nov 19, 2024

Brain Cancer Treatment Market Growth Overview Future - openPR

Nov 19, 2024
pulisher
Nov 18, 2024

Y-mAbs Therapeutics (NASDAQ:YMAB) Now Covered by Analysts at Oppenheimer - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

Beyond The Numbers: 4 Analysts Discuss Y-mAbs Therapeutics Stock - Benzinga

Nov 18, 2024
pulisher
Nov 18, 2024

Institutional investors in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) lost 25% last week but have reaped the benefits of longer-term growth - Yahoo Finance

Nov 18, 2024
pulisher
Nov 17, 2024

HC Wainwright Reaffirms Buy Rating for Y-mAbs Therapeutics (NASDAQ:YMAB) - Defense World

Nov 17, 2024
pulisher
Nov 16, 2024

Y-mAbs Therapeutics' (YMAB) Buy Rating Reaffirmed at HC Wainwright - MarketBeat

Nov 16, 2024
pulisher
Nov 16, 2024

Trading (YMAB) With Integrated Risk Controls - Stock Traders Daily

Nov 16, 2024
pulisher
Nov 15, 2024

YMAB FY2024 EPS Forecast Increased by Cantor Fitzgerald - Defense World

Nov 15, 2024
pulisher
Nov 14, 2024

Asia Deal Watch: Apollo Takes A Shine To Chinese Biotech’s Cardiometabolic Candidate - Scrip

Nov 14, 2024
pulisher
Nov 14, 2024

Cantor Fitzgerald Issues Positive Outlook for YMAB Earnings - MarketBeat

Nov 14, 2024
pulisher
Nov 13, 2024

Investors might be losing patience for Y-mAbs Therapeutics' (NASDAQ:YMAB) increasing losses, as stock sheds 13% over the past week - Simply Wall St

Nov 13, 2024
pulisher
Nov 11, 2024

Leptomeningeal Metastases Clinical Trials 2024: FDA - openPR

Nov 11, 2024
pulisher
Nov 11, 2024

Y-mAbs Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate DevelopmentsY-mAbs Therapeutics, a biopharmaceutical company focusing on innovative radioimmunotherapy and antibody-based products for cancer treatment, rec - Defense World

Nov 11, 2024
pulisher
Nov 10, 2024

Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Down After Earnings Miss - Defense World

Nov 10, 2024
pulisher
Nov 10, 2024

Earnings call: Y-mAbs Therapeutics reports Q3 2024 financials - Investing.com India

Nov 10, 2024
pulisher
Nov 09, 2024

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 09, 2024
pulisher
Nov 09, 2024

Y-mAbs Therapeutics (NASDAQ:YMAB) Issues Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat

Nov 09, 2024
pulisher
Nov 09, 2024

Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ... By GuruFocus - Investing.com Canada

Nov 09, 2024
pulisher
Nov 09, 2024

Y-mAbs Therapeutics Inc (YMAB) Quarterly 10-Q Report - Quartzy

Nov 09, 2024
pulisher
Nov 08, 2024

Y-mAbs Reports Third Quarter 2024 Financial Results - TipRanks

Nov 08, 2024
pulisher
Nov 08, 2024

Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap DownShould You Sell? - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

Y-mAbs Therapeutics, Inc. Reiterates Earnings Guidance for the Year 2024 - Marketscreener.com

Nov 08, 2024
pulisher
Nov 08, 2024

Y mAbs Therapeutics earnings missed by $0.01, revenue fell short of estimates - Investing.com Canada

Nov 08, 2024
pulisher
Nov 08, 2024

Y-mAbs Therapeutics Inc Reports Q3 2024 Revenue of $18.5 Million - GuruFocus.com

Nov 08, 2024
pulisher
Nov 08, 2024

Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments - The Manila Times

Nov 08, 2024
pulisher
Nov 08, 2024

Y-mAbs Q3 Revenue Falls 10%, But Secures Key Japan Deal and Patent Extension | YMAB Stock News - StockTitan

Nov 08, 2024
pulisher
Nov 07, 2024

Examining the Future: Y-mAbs Therapeutics's Earnings Outlook - Benzinga

Nov 07, 2024
pulisher
Nov 07, 2024

What To Expect From Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earni - GuruFocus.com

Nov 07, 2024
pulisher
Nov 07, 2024

What To Expect From Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings - Yahoo Finance

Nov 07, 2024
pulisher
Nov 06, 2024

Exclusive License Agreement Between Y-mAbs Therapeutics, Inc. and Nobelpharma Co., Ltd. for Development and Commercialization of DANYELZA(R) in Japan - Defense World

Nov 06, 2024
pulisher
Nov 05, 2024

(YMAB) Trading Advice - Stock Traders Daily

Nov 05, 2024
pulisher
Nov 05, 2024

Vanguard Group Inc's Strategic Acquisition in Y-mAbs Therapeutics Inc - GuruFocus.com

Nov 05, 2024
pulisher
Nov 05, 2024

Y-mAbs enters Japan market with Nobelpharma for cancer therapy By Investing.com - Investing.com Canada

Nov 05, 2024
pulisher
Nov 04, 2024

Y-mAbs enters Japan market with Nobelpharma for cancer therapy - Investing.com

Nov 04, 2024
pulisher
Nov 04, 2024

Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan - The Manila Times

Nov 04, 2024
pulisher
Nov 02, 2024

Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 02, 2024
pulisher
Nov 01, 2024

Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know - MSN

Nov 01, 2024
pulisher
Nov 01, 2024

Y-mAbs Therapeutics (YMAB) Scheduled to Post Quarterly Earnings on Friday - Defense World

Nov 01, 2024
pulisher
Nov 01, 2024

Y-mAbs Therapeutics (YMAB) Scheduled to Post Earnings on Friday - MarketBeat

Nov 01, 2024
pulisher
Oct 30, 2024

Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights - Benzinga

Oct 30, 2024
pulisher
Oct 29, 2024

Y-mAbs Therapeutics Investors Get Final OK For $19.7M Deal - Law360

Oct 29, 2024
pulisher
Oct 29, 2024

Leptomeningeal Metastases Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Y-mAbs Therapeutics, Plus Therapeutics, AngioChem, AstraZeneca - The Globe and Mail

Oct 29, 2024
pulisher
Oct 27, 2024

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Oct 27, 2024
pulisher
Oct 25, 2024

Objective long/short (YMAB) Report - Stock Traders Daily

Oct 25, 2024
pulisher
Oct 25, 2024

Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast - The Manila Times

Oct 25, 2024
pulisher
Oct 25, 2024

Y-Mabs Therapeutics Inc (YMAB-Q) QuotePress Release - The Globe and Mail

Oct 25, 2024

Finanzdaten der Y Mabs Therapeutics Inc-Aktie (YMAB)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Kapitalisierung:     |  Volumen (24h):